Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

被引：0
|
作者：
Miltiades, Paraskevi [1 ]
Bouchliou, Irene [1 ]
Nakou, Evangelia [1 ]
Spanoudakis, Emmanuil [1 ]
Papageorgiou, Sotirios [2 ]
Pappa, Vasiliki [2 ]
Papaioannou, Maria [3 ]
Moustakidis, Eleytherios [1 ]
Vakalopoulou, Sofia [4 ]
Garipidou, Vasilia [4 ]
Tsatalas, Konstantinos [1 ]
Kotsianidis, Ioannis [1 ]
机构：
[1] Democritus Univ Thrace, Alexandroupolis, Greece
[2] Univ Gen Hosp Atticon, Dept Internal Med 2, Hematol Unit, Athens, Greece
[3] Aristotle Univ Thessaloniki, AHEPA Hosp, GR-54006 Thessaloniki, Greece
[4] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Hippokrat Hosp, GR-54006 Thessaloniki, Greece
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1203 / 1204
页数：2
相关论文
共 50 条
  • [31] In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS
    Freudenreich, Markus
    Tischer, Johanna
    Kroell, Tanja
    Kremser, Andreas
    Dreyssig, Julia
    Beibl, Christine
    Liepert, Anja
    Kolb, Hans J.
    Schmid, Christoph
    Schmetzer, Helga
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 104 - 118
  • [32] Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group
    Mpakou, Vassiliki
    Spathis, Aris
    Bouchla, Anthi
    Tsakiraki, Zoi
    Kontsioti, Frieda
    Papageorgiou, Sotirios
    Bazani, Efthymia
    Gkontopoulos, Konstantinos
    Thomopoulos, Thomas
    Glezou, Irene
    Galanopoulos, Athanasios
    Symeonidis, Argiris
    Diamantopoulos, Panagiotis T.
    Viniou, Nora-Athina
    Kontandreopoulou, Christina-Nefeli
    Zafeiropoulou, Kalliopi
    Kotsianidis, Ioannis
    Lamprianidou, Eleftheria
    Foukas, Periklis
    Mpamias, Aristoteles
    Pappa, Vasiliki
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (02) : 231 - 242
  • [33] Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q
    Gohring, Gudrun
    Lange, Kathrin
    Hofmann, Winfried
    Nielsen, Kirsten Vang
    Hellstrom-Lindberg, Eva
    Roy, Lydia
    Morgan, Michael
    Kreipe, Hans
    Buesche, Guntram
    Giagounidis, Aristoteles
    Schlegelberger, Brigitte
    BLOOD, 2010, 116 (21) : 18 - 18
  • [34] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    BLOOD, 2013, 122 (21)
  • [35] MIDOSTAURIN (MIDO) DEMONSTRATES A FAVORABLE SAFETY PROFILE IN OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
    Fischer, T.
    Kantarjian, H.
    Feldman, E.
    Ehninger, G.
    Larson, P.
    Khan, M.
    Virkus, J.
    Stone, R.
    HAEMATOLOGICA, 2013, 98 : 30 - 30
  • [36] Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry
    Buckstein, Rena
    Wells, Richard A.
    Zhu, Nancy
    Nevill, Thomas J.
    Leitch, Heather A.
    Yee, Karen W. L.
    Leber, Brian
    Sabloff, Mitchell
    Kumar, Rajat
    Geddes, Michelle
    Shamy, April
    Levitt, Max
    Lenis, Martha
    Mamedov, Alex
    Zhang, Liying
    Alibhai, Shabbir M. H.
    BLOOD, 2014, 124 (21)
  • [37] Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02
    Stein, Anthony S.
    Watson, Drew
    Nair, Prashant Ramachandran
    Basu, Kabya
    Ullal, Yashaswini S.
    Ghosh, Adity
    Narvekar, Yugandhara
    Grover, Himanshu
    Sahu, Diwyanshu
    Prakash, Annapoorna
    Behura, Liptimayee
    Balakrishnan, Veena
    Roy, Kunal Ghosh
    Rajagopalan, Swaminathan
    Alam, Aftab
    Parashar, Rajan
    Mundkur, Nirjhar
    Christie, James
    Macpherson, Michele Dundas
    Kapoor, Shweta
    Marcucci, Guido
    BLOOD, 2020, 136
  • [38] Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02.
    Stein, Anthony Selwyn
    Watson, Drew
    Kapoor, Shweta
    Roy, Kunal Ghosh Ghosh
    Alam, Aftab
    Sahu, Diwyanshu
    Basu, Kabya
    Prakash, Annapoorna
    Ullal, Yashaswini
    Raju, Karthik Sundara
    Suseela, Rakhi Purushothaman
    Joseph, Vishwas
    Basu, Sayani
    Kumar, Chandan
    Mohapatra, Subrat
    Kumari, Pallavi
    Birajdar, Shivgonda
    Gopi, Reshma
    Mitra, Upasana
    Marcucci, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DCleu)
    Ansprenger, Christian
    Amberger, Daniel Christoph
    Schmetzer, Helga Maria
    CLINICAL IMMUNOLOGY, 2020, 217
  • [40] Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Demakos, Erin P.
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2013, 122 (21)
12345